Total trials
176
Active
79
Phase 3
15
Total enrollment
86,327
Pipeline matrix
Showing 13 of 13 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| BRCA testing | — | — | — | — | — | 1 | |
| Prasterone | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | 2 | ||
| Pembrolizumab | — | — | — | — | — | 2 | |
| Temozolomide | — | — | — | — | — | 1 | |
| Atezolizumab in combination with Cyclophosphamide and Vinorelbine | — | — | — | — | — | 1 | |
| elacestrant and exemestane | — | — | — | — | — | 1 | |
| Tamoxifen 10 mg | — | — | — | — | — | 1 | |
| Prospective exploratory cohort | — | — | — | — | — | 1 | |
| Neoadjuvant standard treatment for HER2+ | — | — | — | — | — | 1 | |
| Adjuvant standard treatment for HER2+ | — | — | — | — | — | 1 | |
| Sophia DDM | — | — | — | — | — | 1 | |
| ctDNA detection | — | — | — | — | — | 1 |
Next readouts
- 2024-12-01
- 2024-12-31
- 2025-03
- 2025-12
- 2025-12-30
- 2026-12-15
- 2027-01-01
- 2027-04
- 2027-11
- 2028-12
Top conditions
- Breast Cancer39
- Colorectal Cancer6
- Head and Neck Cancer6
- Lung Cancer6
- Cancer6
- Prostate Cancer5
- Metastatic Breast Cancer5
- Neuroendocrine Neoplasm4
Frequently asked questions about European Institute of Oncology
- How many clinical trials does European Institute of Oncology have on ClinicalTrials.gov?
- European Institute of Oncology is listed as the lead sponsor on 176 clinical trials in ClinicalTrials.gov, 79 of which are currently active (recruiting, enrolling, or ongoing).
- How many of European Institute of Oncology's trials are in Phase 3?
- 15 of European Institute of Oncology's trials are in Phase 3, spread across 13 active drug programs.
- What therapeutic areas does European Institute of Oncology focus on?
- European Institute of Oncology's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Cancer.
- When are European Institute of Oncology's next clinical trial readouts?
- European Institute of Oncology has 10 upcoming primary-completion readouts tracked here; the soonest is “Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer”, expected around 2024-12-01.